SF-36 Health Survey Update

Ware, Jr. John E.

doi:10.1097/00007632-200012150-00008

Cited by 4,065 publications

(3,506 citation statements)

References 51 publications

Supporting

Mentioning

3,338

Contrasting

Unclassified

124

Order By: Relevance

“…Health‐related quality of life during the past 4 weeks was assessed with the Japanese version23 of the 36‐item Short Form Health Survey (SF‐36v2) Mental Component Summary (MCS) and Physical Component Summary (PCS) scores, normed to a mean of 50 (standard deviation [SD] of 10) based on the US population, with higher scores indicating better health 24, 25. In addition, the Short Form 6‐Dimension (SF‐6D) utility score was calculated, a preference‐based single index measure for health based on SF‐36 data, weighted according to general population values for health, with a hypothetical range of 0–1.0, where 1.0 indicates “full health” 26…”

Section: Methodsmentioning

confidence: 99%

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey

Arima

Gupta

Gadkari

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Atopic dermatitis is a chronic inflammatory skin disease. The objective of this study was to characterize the burden of atopic dermatitis in Japanese adult patients relative to the general population. Japanese adults (≥18 years) with a self‐reported diagnosis of atopic dermatitis and adult controls without atopic dermatitis/eczema/dermatitis were identified from the 2013 Japan National Health and Wellness Survey. Atopic dermatitis patients were propensity‐score matched with non‐atopic dermatitis controls (1:2 ratio) on demographic variables. Patient‐reported outcome data on comorbidities, mood and sleep disorders, health‐related quality of life, work productivity and activity impairment, and health‐care resource utilization were analyzed in atopic dermatitis patients and matched controls. A total of 638 Japanese adult patients with atopic dermatitis were identified, of whom 290 (45.5%) rated their disease as “moderate/severe” and 348 (54.5%) as “mild”. The analysis cohort comprised 634 atopic dermatitis patients and 1268 matched controls. Atopic dermatitis patients reported a significantly higher prevalence of arthritis, asthma, nasal allergies/hay fever, anxiety, depression and sleep disorders compared with controls (all P < 0.001). Atopic dermatitis patients also reported a significantly poorer health‐related quality of life, higher overall work and activity impairment, and higher health‐care resource utilization (all P < 0.001). Self‐rated disease severity was not associated with disease burden, except for a significantly higher overall work and activity impairment. In conclusion, Japanese adult patients with atopic dermatitis reported a substantial disease burden relative to adults without atopic dermatitis, suggesting an unmet need for effective strategies targeting disease management.

show abstract

Section: Methodsmentioning

confidence: 99%

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey

Arima

Gupta

Gadkari

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The Centre for Epidemiological Studies – Depression Scale (CES‐D) was used to measure levels of depressive symptomatology, ranging from 0 to 60 (indicating a low to high level of depressive state) (Radloff, 1977). The psychometric properties of the NRS‐11 (Jensen et al., 1986), reliability and validity of the SF‐36 (Ware, 2000) and test–retest reliability and validity of the CES‐D (Devins et al., 1988) have been investigated with good results. The presence and severity of comorbid conditions (Table 1) were measured using a previously validated inventory (Vermeulen, 2006).…”

Section: Methodsmentioning

confidence: 99%

A population‐based, incidence cohort study of mid‐back pain after traffic collisions: Factors associated with global recovery

Johansson

Boyle

Hartvigsen

et al. 2015

European Journal of Pain

View full text Add to dashboard Cite

BackgroundTraffic collisions often result in a wide range of symptoms included in the umbrella term whiplash‐associated disorders. Mid‐back pain (MBP) is one of these symptoms. The incidence and prognosis of different traffic injuries and their related conditions (e.g. neck pain, low back pain, depression or others) has been investigated previously; however, knowledge about traffic collision‐related MBP is lacking. The study objectives were to describe the incidence, course of recovery and prognosis of MBP after traffic collisions, in terms of global self‐reported recovery.MethodsLongitudinal data from a population‐based inception cohort of all traffic injuries occurring in Saskatchewan, Canada, during a 2‐year period were used. Annual overall and age‐sex‐specific incidence rates were calculated, the course of recovery was described using the Kaplan–Meier technique, and associations between participant characteristics and time‐to‐self‐reported recovery were explored in 3496 MBP cases using Cox proportional hazards models.ResultsThe yearly incidence rate was 236 per 100,000 population during the study period, and was highest in women and in young persons. The median time‐to‐first reported recovery was 101 days (95% CI: 99–104) and about 23% were still not recovered after 1 year. Participant's expectation for recovery, general health, extent of severely affecting comorbidities and having experienced a previous traffic injury were some of the prognostic factors identified.ConclusionsThese findings show that MBP is common after traffic collisions, may result in a long recovery process and that a range of biopsychosocial factors are associated with recovery.

show abstract

“…Physical and mental health functioning were assessed using the Short Form‐36 (SF‐36; version 2),26, 27 a widely used 36‐item questionnaire measuring functional health status across eight domains. The physical and mental component scores (PCS and MCS respectively) are derived from the eight domain scores, and range from 0 to 100, with higher scores indicating better health functioning 26, 27.…”

Section: Methodsmentioning

confidence: 99%

“…The physical and mental component scores (PCS and MCS respectively) are derived from the eight domain scores, and range from 0 to 100, with higher scores indicating better health functioning 26, 27. The mean score for the PCS and MCS is 50, with scores below 45 indicating impairment relative to the general population 28…”

Section: Methodsmentioning

confidence: 99%

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Griffiths

Vender

Sofen

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundTofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re‐treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re‐treatment was effective in patients with chronic plaque psoriasis.ObjectivesTo describe the effects of tofacitinib withdrawal/re‐treatment on health‐related quality of life (HRQoL) and disease symptoms measured by patient‐reported outcomes (PROs).MethodsThe study was divided into initial treatment, treatment withdrawal, and re‐treatment periods. Initial treatment: patients were randomized to receive tofacitinib 5 (n = 331) or 10 mg (n = 335) BID for 24 weeks. Treatment withdrawal: patients who achieved both ≥ 75% reduction in Psoriasis Area and Severity Index (PASI) score from baseline and Physician's Global Assessment of ‘clear’/‘almost clear’ at Week (W)24 received placebo (withdrawal) or the previous dose (continuous treatment). Re‐treatment: at relapse (> 50% loss of W24 PASI response) or at W40, patients received their initial tofacitinib dose. PROs included: Dermatology Life Quality Index (DLQI), Itch Severity Item (ISI), Short Form‐36 (SF‐36) and Patient's Global Assessment (PtGA).ResultsAfter initial treatment with tofacitinib 5 and 10 mg BID, substantial and significant improvements were reported for mean DLQI (baseline: 12.6 and 12.6; W24: 5.1 and 2.6) and ISI (baseline: 6.7 and 6.9; W24: 2.9 and 1.6). Patients continuously treated with tofacitinib 5 and 10 mg BID maintained those improvements through Week 56 (DLQI: 3.0 and 2.1; ISI: 2.3 and 1.4). By W40, patients withdrawn from tofacitinib 5 and 10 mg BID showed worsening in DLQI (5.0 and 6.2) and ISI (3.7 and 4.0) scores; improvements were regained upon re‐treatment (W56, DLQI: 3.4 and 2.4; ISI: 2.2 and 1.6). Similar results were reported for PtGA and SF‐36.ConclusionContinuous tofacitinib treatment provided sustained improvement in HRQoL and disease symptoms. Patients randomized to treatment withdrawal lost initial improvements. Upon re‐treatment, improvements were recaptured to levels comparable to those seen with continuous treatment.

show abstract

SF-36 Health Survey Update

Cited by 4,065 publications

References 51 publications

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey

A population‐based, incidence cohort study of mid‐back pain after traffic collisions: Factors associated with global recovery

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Contact Info

Product

Resources

About